Jump to content

Mammoth Biosciences

Add links
From Wikipedia, the free encyclopedia
Mammoth Biosciences
Company typePrivate
IndustryBiotechnology
Founded2017
FounderJennifer Doudna

Trevor Martin Janice Chen

Lucas Harrington
HeadquartersBrisbane, California, United States
Websitehttps://mammoth.bio

Mammoth Biosciences is a biotechnology company based in Brisbane, California[1] developing diagnostic tests using CRISPR-Cas12a and CRISPR-based therapies using its proprietary ultra-small CRISPR systems. Several CRISPR-Cas systems identified through the company's metagenomics-based protein discovery platform, including members of the Casφ and Cas14 families of CRISPR-associated enzymes, have demonstrated potential for therapeutic genome editing in in vivo settings.[2]

History

[edit]

The company was founded in 2017[3] by Jennifer Doudna, Janice Chen, and Lucas Harrington of the University of California, Berkeley, and Trevor Martin of Stanford University.[4] Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in Chinese hamster ovary cells.[5] Also in 2020, both Mammoth Biosciences and Sherlock Biosciences from the Broad Institute used their similar CRISPR technologies to develop tests for COVID-19.[6] The technology, which is owned under the trademark of DETECTR BOOST, has been contracted to be manufactured by Merck & Co.[7]

In 2023, the company announced that it will focus on developing CRISPR-based therapies.[8] The company's platform uses "ultra-small" Cas enzymes, such as CasΦ and Cas14,  which measure down to a third or less the size of Cas9, and which could allow for easier delivery in vivo through commonly used non-viral and viral delivery mechanisms, including adeno-associated virus vectors.[9] [10] Compared to Cas9, CasΦ and Cas14 may also offer less restrictive protospacer adjacent motif requirements, advantageous off-target activity, and allele-specific editing capabilities, which could broaden the range of targetable diseases in the genome.[10] [9] Mammoth previously announced partnerships with Vertex Pharmaceuticals (2021) and Bayer (2022) to research ultra-small CRISPR systems for in vivo editing.[11][12]

[edit]
  • Lucas B. Harrington et al. ,Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science362,839-842(2018). doi:10.1126/science.aav4294
  • Broughton, J.P., Deng, X., Yu, G. et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol 38, 870–874 (2020). https://doi.org/10.1038/s41587-020-0513-4
  • Patrick Pausch et al. ,CRISPR-CasΦ from huge phages is a hypercompact genome editor. Science369,333-337(2020). doi:10.1126/science.abb1400

See also

[edit]

References

[edit]
  1. ^ Fannin, Rebecca (2022-03-12). "The 30-year-old female founder at the forefront of a billion-dollar bet on CRISPR gene editing". CNBC. Retrieved 2023-08-14.
  2. ^ "News: Miniscule Cas nucleases do a Mammoth's job". CRISPR Medicine. Retrieved 2023-11-10.
  3. ^ "Mammoth Biosciences". Craft.co. Archived from the original on 2021-05-27. Retrieved 2021-05-27.
  4. ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 422–423. ISBN 978-1-9821-1585-2.
  5. ^ "Horizon Discovery, Mammoth Biosciences Sign Second CRISPR Tools Development Agreement". Genomeweb. 2020-01-13. Retrieved 2021-05-27.
  6. ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 427–433. ISBN 978-1-9821-1585-2.
  7. ^ Mcardle, Matthew (May 17, 2021), Increasing SARS-CoV-2 testing capacity with CRISPR-based rapid testing, SelectScience, retrieved September 9, 2021{{citation}}: CS1 maint: date and year (link)
  8. ^ "CRISPR unicorn Mammoth backs off diagnostics research, laying off 35 on testing team to focus on therapeutics". Endpoints News. Retrieved 2023-09-19.
  9. ^ a b Harrington, Lucas B.; Burstein, David; Chen, Janice S.; Paez-Espino, David; Ma, Enbo; Witte, Isaac P.; Cofsky, Joshua C.; Kyrpides, Nikos C.; Banfield, Jillian F.; Doudna, Jennifer A. (2018-11-16). "Programmed DNA destruction by miniature CRISPR-Cas14 enzymes". Science. 362 (6416): 839–842. Bibcode:2018Sci...362..839H. doi:10.1126/science.aav4294. ISSN 0036-8075. PMC 6659742. PMID 30337455.
  10. ^ a b Pausch, Patrick; Al-Shayeb, Basem; Bisom-Rapp, Ezra; Tsuchida, Connor A.; Li, Zheng; Cress, Brady F.; Knott, Gavin J.; Jacobsen, Steven E.; Banfield, Jillian F.; Doudna, Jennifer A. (2020-07-17). "CRISPR-CasΦ from huge phages is a hypercompact genome editor". Science. 369 (6501): 333–337. Bibcode:2020Sci...369..333P. doi:10.1126/science.abb1400. ISSN 0036-8075. PMC 8207990. PMID 32675376.
  11. ^ Hart, Robert. "Mammoth Biosciences Inks $691 Million Deal With Vertex For Crispr Gene-Editing Therapies". Forbes. Retrieved 2023-09-19.
  12. ^ Burger, Ludwig; Weiss, Patricia (2022-01-10). "Bayer in gene therapy collaboration with Mammoth Biosciences". Reuters. Retrieved 2023-09-19.


Stub icon

This corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mammoth_Biosciences&oldid=1220349488"